Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thrombocytapheresis as a Bridge Intervention in JAK2-Mutant Myeloproliferative Neoplasm Complicated by Acquired von Willebrand Disease: A Case Report.

Journal of clinical apheresis - 1 Aug 2026

Naqvi Abbas Ghazi, Tomar Akshaya, Kushwaha Neerja, Maaheraa L Anis

Abstract excerpt

Acquired von Willebrand disease (AvWD) in myeloproliferative neoplasms with extreme thrombocytosis causes paradoxical bleeding due to the mechanism of adsorption and ADAMTS13-mediated proteolysis of high-molecular-weight von Willebrand factor (vWF) multimers. When first-line cytoreductive therapy fails due to intolerance or nonadherence, rapid alternatives are limited. We describe a 74-year-old woman with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Janus Kinase 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myeloproliferative Disorders

Share to Platelet Count

Share to Thrombocytosis

Share to von Willebrand Diseases

Share to von Willebrand Factor

Source

Identifiers

PMID: 42366589
DOI: 10.1002/jca.70152

Genes

ADAMTS13
JAK2
TEC

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Thrombocytapheresis as a Bridge Intervention in JAK2-Mutant Myeloproliferative Neoplasm Complicated by Acquired von Willebrand Disease: A Case Report.PMID 42366589Read ↗

Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants.Semantic proximity Read ↗

Isolated Extreme Thrombocytosis as the Presenting Feature of Chronic Myeloid Leukemia-An Unusual Phenotype Treated With Plateletpheresis.Semantic proximity Read ↗

[Acquired von Willebrand syndrome: from diagnosis to treatment].Semantic proximity Read ↗

Discrepant low von Willebrand factor activity results on the ACL TOP analyzer are frequent in unselected patients with myeloproliferative neoplasms and show no correlation with high-molecular-weight multimer loss or bleeding phenotype.Semantic proximity Read ↗

The anti-von Willebrand factor aptamer ARC1779 increases von Willebrand factor levels and platelet counts in patients with type 2B von Willebrand disease.Semantic proximity Read ↗

Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations.Semantic proximity Read ↗

Von Willebrand factor as a potential predictive biomarker of early complications of endothelial origin after allogeneic hematopoietic cell transplantation.Semantic proximity Read ↗

Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study.Semantic proximity Read ↗

A Case of Coomb’s Negative Hemolysis Post-mRNA COVID-19 Vaccine in a Patient With Polycythemia VeraSemantic proximity Read ↗

An ASTCT, CIBMTR, EBMT, and APBMT Consensus Statement Defining Response Criteria for Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy (TA-TMA) Directed TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.